Navigation Links
OPKO Health To Acquire PROLOR Biotech
Date:4/23/2013

ny of PROLOR's compounds under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available products, as well as products under development by others, may prove to be as or more effective than PROLOR's products for the indications being studied, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in OPKO's and PROLOR's filings with the Securities and Exchange Commission, the ability to obtain regulatory approvals for the transaction on the proposed terms and schedule; the failure of OPKO's or PROLOR's stockholders to approve the transaction; the risk that a condition to closing of the merger may not be satisfied; the time required to consummate the proposed merger; the focus of management on merger-related issues; the risk that the businesses will not be integrated successfully; the risk that any potential synergies from the transaction may not be fully realized or may take longer to realize than expected; new information arising out of clinical trial results; and the risk that the safety and/or efficacy results of existing clinical trials will not support continued clinical development, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new pr
'/>"/>
SOURCE OPKO Health, Inc.; PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. California Healthcare Institute Announces Executive Promotion
2. Healthcare Sales Hiring Slowly on the Rise
3. Bayer CropScience Promotes Bee Health Awareness and Collaboration
4. A Prescription for an Ailing Health Care System
5. Kitware to Develop a Universal Healthcare Exchange Language Infrastructure
6. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
7. Start a Healthy Tradition this Earth Day: Tips from Topical BioMedics on How to Detox the Family Medicine Cabinet
8. TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013
9. Online Courses Address Latest Healthcare Compliance Regulations
10. Cambridge College School of Management Program Hosts a Panel Discussion On Trends and Opportunities In Health Information Technology
11. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... September 19, 2014 The new , ... , available today on PharmaBoardroom.com for ... crisis that rocked the Spanish economy in 2009, and the ... community has remained pragmatic in times of trouble. ... the fifth biggest European market, and the general conditions to ...
(Date:9/18/2014)... A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
(Date:9/18/2014)... Research and Markets has announced ... Cell Industry Report, 2014-2017" report to their offering. ... that can differentiate into specialized cells and can divide ... therapy can be applied to treatment of cardiovascular diseases, ... diseases, damage or lesion of liver, kidney and other ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... body, then alarm bells start ringing. Such clumps, ... type 2 diabetes, formerly called adult-onset diabetes. If ... might be able to treat such diseases more efficiently. ... the Helmholtz-Zentrum Dresden-Rossendorf and the university in Aarhus, Denmark, ...
... The Plasma Protein Therapeutics Association (PPTA) applauds the ... Drugs Act ( H.R. 2672 ) and ( S. ... therapies that treat patients with rare diseases by eliminating barriers ... on plasma protein therapies are coping with a very rare ...
... (NASDAQ: GPRO ) today reported financial results for ... million and non-GAAP earnings per share (EPS) of $0.51.   ... products in the second quarter of 2011, while supply chain ... sales a year ago," said Carl Hull, the Company,s president ...
Cached Biology Technology:In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3PPTA Praises Legislation That Protects the Treatment of Rare Diseases 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14
(Date:9/21/2014)... what was previously thought, newborn immune T cells may ... bacteria, according to a new study led by King,s ... to that of adults, babies may still be able ... published in the journal Nature Medicine . , ... types of immune cells, including neutrophils which play an ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Soft robotics 'toolkit' features everything a robot-maker needs 2
... - A study comparing a University of Pennsylvania ... to the traditional American method has shown that 80 ... traditional method are actually at risk for developing osteoarthritis ... The results indicate that traditional scoring of radiographs that ...
... most established fisheries certifier is failing on its promises ... leading fisheries experts from the University of British Columbia ... California at San Diego and elsewhere. Established in ... of the world,s largest fish retailers, the Marine Stewardship ...
... but estrogen might not be the reason. Testosterone, though, could ... the lab of Florida State University researcher Mohamed Kabbaj, associate ... a five-year, $1.8 million grant from the National Institute of ... research team also is working to identify the role of ...
Cached Biology News:Hip dysplasia susceptibility in dogs may be underreported, according to Penn Vet comparative study 2Hip dysplasia susceptibility in dogs may be underreported, according to Penn Vet comparative study 3Hip dysplasia susceptibility in dogs may be underreported, according to Penn Vet comparative study 4Seafood stewardship questionable: UBC-Scripps experts 2Seafood stewardship questionable: UBC-Scripps experts 3Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: